Carolina Barizan Perdão(1) 1. Crop Biolabs
Cell-based therapeutics is a modality with the potential to treat many currently incurable diseases, with notable recent clinical and commercial successes.
However, cell-based therapies continue to face numerous hurdles that limit their commercialization, including identification of the appropriate cell source, generation of a sufficiently viable, potent, and safe product that meets patient- and disease-specific needs, and the development of scalable manufacturing processes.
These obstacles are being addressed with basic research and next-generation engineering approaches, especially through genome and epigenome editing, synthetic biology, and biomaterials.
A paper published by researchers of Cambridge and Rice University (USA) in Nature Reviews, in 2022, discussed the main progress, innovations, and challenges in cell-based therapy and how techniques such as CRISPR–Cas genome editing toolbox; Genome editing for monogenic disease correction; Multiplexed genome editing for robust CAR-T cells; Engineering DNA-encoded regulation, and Strategies to overcome immune rejection for allogeneic cell therapy are solving obstacles to cell-based therapies and products.
Access the full article and learn more: https://doi.org/10.1038/s41573-022-00476-6
Learn more about Crop Biolabs services for cell-based products: https://cropbiolabs.com.br/
